In this episode, we review the ISAR-REACT 5 trial and hear Dr. Steve Dunn’s thoughts about how this trial fits into P2Y12 management in patients with acute coronary syndromes.
Episode:
0:00-0:40: Intro
0:41-1:23: Introduction of Dr. Steve Dunn
1:24-3:42: ISAR-REACT 5 Overview
3:43-6:28: Steve’s Overall Thoughts
6:29-7:59: Context of ISAR-REACT 5
8:00-9:34: Study Funding
9:35-11:25: Study Discontinuation Rate
11:26-12:50: Secondary Safety Outcomes
12:51-15:51: Final Thoughts
15:52-16:50: Closing/Podcast Recording Location Discussion
References:
- ISAR-REACT 5: Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 2019;381:1524-1534.
- TRITON-TIMI: Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009;357:2001-2015.
- PLATO: Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009;361:1045-1057.
- PRAGUE-18: Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study. Circulation 2016;134(21):1603-1612.
- TRILOGY-ACS: Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. N Engl J Med 2012;367:1297-1309.
- ACCOAST: Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. N Engl J Med 2013;369:999-1010.
CardioScripts 